As the study investigators have showing that the combination of a vaccination; and a medicating cream is a promising strategy to dramatically reduce the recurrence of genital herpes. But by a new approach for a herpes simplex virus vaccine uses a vaccine to prime and a chemoattractant to pull immune cells into the genital tract. Herpes simplex virus (HSV) type 2; which causes genital herpes, is very common, affecting more than 400 million people worldwide.
As there isno cure and efforts to develop a vaccine have had limited success. The study testing a novel vaccine strategy; known as prime and pull, in guinea pigs infected with genital herpes. The prime involves a vaccine that generates a response to the virus from T cells, highly specialized immune cells. The pull consists of a cream containing imiquimod, a medication commonly used to treat genital warts.
Using combination vaccination
Applied to the affected area, the cream attracts key immune cells to the site of infection where they can block the virus from spreading and causing herpes lesions. the effect of the combination therapy was far greater than either the vaccine or cream alone. It is the first time that a study has showing that prime-and-pull strategy can block existing recurrent disease. Development of a therapeutic HSV vaccine is a high priority.
But in the study exciting results have encouraging and, hopefully others, to pursue this strategy with more vaccines. Vaginal HSV-2 infection, gps were vaccinated with various combination of glycoproteins and adjuvant with or without subcutaneous or local applications of imiquimod after infection. The study team gave three rounds of treatment to the animals, noting that the strategy worked rapidly and beginning with the first round.
Trivalent immunizing group
No effect on recurrent shedding was observed. In the second study, recurrent disease scores were similar in the PBS control group and the trivalent immunizing group treating with subcutaneous imiquimod however, significant reductions with glycoprotein vaccines; and local imiquimod (p < 0.01 vs. placebo) were noting. Although both the vaccines alone and imiquimod alone reduced recurrent HSV disease; the combination of local imiquimod and vaccine was the most effective.
However this strategy, if developed into a therapy for humans; could be a game changer for individuals with recurrent infections or resistance to standard antiviral treatment, said Iwasaki. Active herpes infection causes painful lesions that are physically and emotionally harmful to affected people. the strategy of prime (subunit HSV vaccine) and topical pull (intravaginal/topical imiquimod) decreased recurrent HSV more effectively than vaccine alone.